האיחוד האירופי - לטבית - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfoma, mantle-cell - antineoplastiski līdzekļi - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple mieloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

לטביה - לטבית - Zāļu valsts aģentūra

orion corporation, finland - metotreksāts - tabletes - 2,5 mg

לטביה - לטבית - Zāļu valsts aģentūra

orion corporation, finland - metotreksāts - tabletes - 10 mg

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

eisai gmbh - perampanel - epilepsijas, daļēji - antiepileptics, , citas antiepileptics - fycompa tiek norādīts daļējo iestāšanās lēkmēm ar vai bez sekundāri vispārēja krampju pieaugušo un pusaudžu pacientu no 12 gadu vecuma ar epilepsiju palīglīdzekļa ārstēšanai. fycompa ir norādīts adjunctive ārstēšana primārās vispārēja tonizējoša-clonic atsavināšanas pieaugušo un pusaudžu pacientiem no 12 gadu vecuma ar ģeneralizēta idiopātiska epilepsija.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

glaxo group limited  - retigabine - epilepsija - antiepileptics, - trobalt, kas norādīts kā palīglīdzekļa attieksmi pret narkotiku rezistentu daļējo iestāšanās lēkmēm ar vai bez sekundārā vispārināšana pacientēm 18 gadus veciem vai vecākiem ar epilepsiju, kur citu atbilstīgu narkotiku kombinācijas, ir izrādījušies neatbilstīgi vai nav bijuši panes.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

bial - portela ca, s.a. - eslikarbazepīna acetāts - epilepsija - antiepileptics, - exalief ir indicēts kā papildterapija pieaugušajiem ar daļējas krampju lēkmes ar sekundāru ģeneralizāciju vai bez tās.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbazepīna acetāts - epilepsija - antiepileptics, - zebinix ir indicēts kā papildterapija pieaugušajiem, pusaudžiem un bērniem vecumā virs 6 gadiem ar daļējas krampju lēkmes ar sekundāru ģeneralizāciju vai bez tās.

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiski līdzekļi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.